Trinity Biotech (TRIB) Total Current Liabilities (2009 - 2025)

Trinity Biotech has disclosed Total Current Liabilities across 17 years of filings, most recently posting $141.2 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $141.2 million, up 339.97% year-over-year; the trailing twelve-month figure through Dec 2025 was $141.2 million (up 339.97% YoY), and the FY2025 annual result was $141.2 million, up 339.97% from the prior year.
• Total Current Liabilities came in at $141.2 million for Q4 2025 at Trinity Biotech, up from $31.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $141.2 million in Q4 2025 to a low of $12.7 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $24.3 million (2024), against an average of $41.3 million.
• Across the five-year window, Total Current Liabilities surged 364.27% in 2021 and plunged 86.86% in 2022, its largest moves.
• Trinity Biotech's Total Current Liabilities stood at $100.5 million in 2021, then tumbled by 82.75% to $17.3 million in 2022, then retreated by 13.29% to $15.0 million in 2023, then soared by 113.47% to $32.1 million in 2024, then jumped by 339.97% to $141.2 million in 2025.
• The last three Total Current Liabilities figures came in at $141.2 million (Q4 2025), $31.5 million (Q2 2025), and $32.1 million (Q4 2024), per Business Quant data.